title: An oral carcinogenicity and toxicity study of senna (Tinnevelly senna fruits) in the rat.
abstract: Senna (Tinnevelly senna fruits), a known laxative derived from plants, was administered by gavage to Sprague-Dawley (Crl:CD (SD) BR) rats once daily at dose levels of 0, 25, 100 and 300 mg/kg/day for up to 104 consecutive weeks. Based upon clinical signs related to the laxation effect of senna, the highest dose (300 mg/kg/day) was considered to be a maximum tolerated dose. Sixty animals per sex were assigned to the control and dose groups. Assessments included clinical chemistry, hematology, full histology (control and high-dose groups; in addition, low and mid dose: intestinal tract, adrenals, liver, kidneys, brain and gross lesions) and toxicokinetics. The primary treatment-related clinical observation was mucoid feces seen at 300 mg/kg/day. When compared to controls, animals administered 300 mg/kg/day had slightly reduced body weights, increased water consumption and notable changes in electrolytes in serum (increases in potassium and chloride) and urine (decreases in sodium, potassium and chloride). The changes in electrolytes are most likely physiologic adaptations to the laxative effect of senna. At necropsy, dark discoloration of the kidneys was observed in animals in all treated groups. Histological changes were seen in the kidneys of animals from all treated groups and included slight to moderate tubular basophilia and tubular pigment deposits. In addition, for all treated groups, minimal to slight hyperplasia was evident in the colon and cecum. These histological changes, together with the changes seen in the evaluation of clinical chemistry and urine parameters, have been shown to be reversible in a previous 13-week rat study of senna. No treatment-related neoplastic changes were observed in any of the examined organs. Based upon these data, it is concluded that senna is not carcinogenic even after daily administration for 2 years at dosages of up to 300 mg/kg/day in Sprague-Dawley rats.
authors.affiliation: Purdue Pharma, Ardsley, NY, USA.
authors.forename: J M
authors.initials: JM
authors.lastname: Mitchell
authors.forename: U
authors.initials: U
authors.lastname: Mengs
authors.forename: S
authors.initials: S
authors.lastname: McPherson
authors.forename: J
authors.initials: J
authors.lastname: Zijlstra
authors.forename: P
authors.initials: P
authors.lastname: Dettmar
authors.forename: R
authors.initials: R
authors.lastname: Gregson
authors.forename: J C
authors.initials: JC
authors.lastname: Tigner
mesh_terms: D000284:Administration, Oral; D000818:Animals; D001835:Body Weight / Q000187:drug effects; D015197:Carcinogenicity Tests; D002400:Cathartics / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D004326:Drinking / Q000187:drug effects; D005638:Fruit; D006801:Humans; D007422:Intestines / Q000187:drug effects* / Q000473:pathology; D007441:Intubation, Gastrointestinal; D007668:Kidney / Q000187:drug effects* / Q000473:pathology; D008297:Male; D020714:Maximum Tolerated Dose; D051381:Rats; D017207:Rats, Sprague-Dawley; D012676:Senna Extract / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000633:toxicity*; D029846:Senna Plant; D036401:Toxicity Tests, Chronic
chemical_list: D002400:Cathartics; D012676:Senna Extract